Related Experiment Video
Updated: Nov 25, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis
Emily A Lemke1, Amishi Y Shah1, Matthew Campbell1
1The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Cabozantinib inhibits tyrosine kinase activity at the MET, AXL, and VEGF receptors and is approved for front-line therapy in metastatic clear cell renal cell carcinoma. Little off-protocol data exist on tolerability and response. The objective of this retrospective study was to assess off-protocol tolerability and response rates in patients with metastatic clear cell renal cell carcinoma being treated with cabozantinib. Data on baseline disease characteristics and treatment details were retrospectively gathered for patients with metastatic clear cell renal cell carcinoma treated with cabozantinib at The University of Texas MD Anderson Cancer Center from 2015 to 2017. A blinded radiologist determined the best response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Descriptive statistics were utilized. Cabozantinib has a high disease control rate (92%), even as a late line of therapy in metastatic clear cell renal cell carcinoma. However, careful monitoring is warranted, as many patients require treatment breaks and dose reductions for therapy-related toxicity.
Insights
Cabozantinib shows a high disease control rate (92%) in metastatic clear cell renal cell carcinoma. However, careful monitoring is needed due to frequent treatment breaks and dose reductions for toxicity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Cabozantinib targets MET, AXL, and VEGF receptors.
- It is approved for first-line treatment of metastatic clear cell renal cell carcinoma.
- Limited data exist on off-protocol use, tolerability, and response.
Purpose of the Study:
- To evaluate the off-protocol tolerability and response rates of cabozantinib.
- To assess treatment outcomes in patients with metastatic clear cell renal cell carcinoma receiving cabozantinib outside of standard protocols.
Main Methods:
- Retrospective study of patients with metastatic clear cell renal cell carcinoma treated with cabozantinib (2015-2017).
- Data collected on baseline characteristics and treatment details.
- Response assessed by a blinded radiologist using RECIST 1.1 criteria.
Main Results:
- Cabozantinib demonstrated a high disease control rate of 92%.
- Many patients required treatment interruptions and dose reductions due to toxicity.
- This indicates good efficacy even in later lines of therapy.
Conclusions:
- Cabozantinib is effective in controlling disease in metastatic clear cell renal cell carcinoma.
- Therapy-related toxicities necessitate careful patient monitoring, dose adjustments, and treatment breaks.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
01:06Renal Drug Clearance: Overview
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
01:08Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...